What Are the Challenges in Targeting IDH Mutations in Cancer?
Despite the success of IDH inhibitors, challenges remain. Resistance to targeted therapies can develop, necessitating combination therapies and new treatment approaches. Additionally, not all patients respond to IDH inhibitors, highlighting the need for further research to understand resistance mechanisms and identify biomarkers for response prediction.
